Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Symposium

Immuno-Oncology: Advances in Translating from Bench to Clinic


Speakers: Luis Borges, Deborah Charych, Ravi Majeti, Brian Wong, Juan Jaen, Tara Arvedson, Jason DeVoss, Lelia Delamarre, Cheng Liu
Organizers: Snow Ge (Nektar), Deborah Charych (Nektar), Wenfeng Xu (Genentech)
Date: 2017-06-28
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location: Crowne Plaza, Foster City, CA
Major Sponsor: (2)Celerion; Charles River
Vendor show vendors registered to date: (23)Applied BioMath; Aragen Bioscience, Inc.; BioLegend; Bio-Techne; Cardinal Health; Cellular Dynamics Intl; Covance; CrownBio; Cytovier LLC; Eurofins; Eurofins Discovery; Fujifilm Diosynth Biotechnologies; Intertek; PeproTech Inc; PharmaLegacy; PHARMout Laboratories; PPD; Premier Research; Quintara Discovery (QDI); Science Exchange; Second Genome; ThermoFisher; WuXi Apptec
Registration: http://www.PBSS.org
Registration deadline:2017-06-27  (it will close sooner if the seating cap is reached)

About the Topic

8:45-8:55  Opening Remarks and Introduction

8:55-9:35  Discovery of new drug targets and therapeutic approaches for cancer immunotherapy (Luis Borges, SVP, Five Prime Therapeutics)

9:35-10:15  Harnessing the Potent IL2 Immune Stimulatory Pathway with Designer Polymers (Deborah Charych, ED, Nektar)

10:15-10:25  Major sponsor presentation (Charles River)

10:25-10:40  Break

10:40-11:20  Pre-Clinical Development of a Humanized Anti-CD47 Antibody (Ravi Majeti, Professor, Stanford)

11:20-12:00  Discovery and development of orally-available cancer immunotherapies (Brian Wong, CEO, FLX Bio)

12:00-1:00  Lunch

1:00-1:40  Small Molecules, Antibodies, and Cell-based Therapies in the Fight Against Cancer (Juan Jaen, Founder and President, Arcus Biosciences and PACT Pharma)

1:40-2:20  Blincyto and BiTE® Antibody Platform for Cancer Therapy (Tara Arvedson, Principal Scientist, Amgen)

2:20-2:30  Major sponsor presentation (Celerion)

2:30-2:45  Break

2:45-3:25  T-VEC and oncolytic therapy (Jason DeVoss, Sr. Scientist, Amgen)

3:25-4:05  Personalized Cancer Vaccine (Lelia Delamarre, Sr. Scientist, Genentech)

4:05-4:15  Break

4:15-4:55  After CD19: CAR-T for solid tumor (Cheng Liu, CEO, Eureka)

4:55-5:15  General Q&A


2024-03-07, [In-Person] Project/Program Management Elevating Drug Development
2024-03-15, [Free Online] Oncology Business Development and Partnering: perspectives and advice from buyers
2024-03-28, [In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-09-10, [In-Person] Translational PK/PD considerations for Novel Modalities
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
┬ęPharmaceutical & BioScience Society, International; Last Modified: 2/29/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad